Sugi Predict

Sugi Predict / Compounds / Butixocort

Butixocort

Butixocort

SCHEMBL109157

CCCC(=O)O[C@]1(C(=O)CS)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C

nearest known ligand 0.86

Full drug profile on Sugi Atlas →

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ NR3C2 P08235 8/20 0.86
▸ PGR P06401 4/20 0.86
▸ NR3C1 P04150 3/20 0.86
▸ HIF1A Q16665 9/20 0.79
▸ KMT2A Q03164 2/20 0.79
▸ AR P10275 2/20 0.70
▸ CHRM1 P11229 2/20 0.70
▸ SMN1; SMN2 Q16637 3/20 0.60
▸ MAPT P10636 2/20 0.60
▸ POLB P06746 1/20 0.60
▸ GAA P10253 1/20 0.60
▸ CYP2C19 P33261 2/20 0.59
▸ HSD17B10 Q99714 2/20 0.59
▸ SERPINA6 P08185 2/20 0.59
▸ SHBG P04278 1/20 0.59
▸ CYP3A4 P08684 1/20 0.59
▸ NFKB1 P19838 1/20 0.59
▸ LMNA P02545 2/20 0.57
▸ PMP22 Q01453 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Butixocort SCHEMBL23803956 1.00 NR3C2 (0.86) NR3C2PGRNR3C1HIF1AKMT2A
SCHEMBL11581184 0.93 NR3C2 (0.89) NR3C2PGRNR3C1HIF1AKMT2A
Resocortol Butyrate SCHEMBL2110603 0.93 NR3C2 (0.89) NR3C2PGRNR3C1HIF1AKMT2A
SCHEMBL11581192 0.93 NR3C2 (0.89) NR3C2PGRNR3C1HIF1AKMT2A
SCHEMBL10535271 0.93 NR3C2 (0.80) NR3C2PGRNR3C1HIF1AKMT2A
Hydrocortisone Butyrate SCHEMBL111478 0.92 NR3C2 (1.00) NR3C2PGRNR3C1HIF1AKMT2A
Hydrocortisone Butyrate SCHEMBL21111521 0.92 NR3C2 (1.00) NR3C2PGRNR3C1HIF1AKMT2A
Hydrocortisone Butyrate SCHEMBL14339600 0.92 NR3C2 (1.00) NR3C2PGRNR3C1HIF1AKMT2A
Hydrocortisone Butyrate SCHEMBL14473210 0.92 NR3C2 (1.00) NR3C2PGRNR3C1HIF1AKMT2A
Hydrocortisone Butyrate SCHEMBL14936050 0.92 NR3C2 (1.00) NR3C2PGRNR3C1HIF1AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1607 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12616654-B2 Stainless steel can for pressurised metered dose inhalers CHIESI FARMACEUTICI S.P.A. (IT) 2026-05-05 — — US claimed
EP-4656202-A1 TREATMENT OF ATOPIC DERMATITIS WITH POLYETHYLENE GLYCOL-MODIFIED INTERLEUKIN 2, GLUCOCORTICOID AND HYALURONIC ACID Xie, Yanhui (CN) 2025-12-03 — — EP claimed
EP-4616867-A1 COMBINATION OF ENDOTHELIN RECEPTOR ANTAGONIST AND GLUCOCORTICOID FOR TREATING IGA NEPHROPATHY Sanreno Therapeutics (Shanghai) Limited (CN) 2025-09-17 — — EP claimed
EP-4126138-B1 AEROSOL DELIVERY OF AT LEAST TWO LIQUID COMPOSITIONS INVOX BELGIUM NV (BE) 2024-10-16 — — EP claimed
WO-2024189434-A1 USE OF NADOLOL TO TREAT PULMONARY SYMPTOMS ASSOCIATED WITH INFECTIONS WITH SARS-CoV-2 CHRONIC AIRWAY THERAPEUTICS LIMITED (AU) 2024-09-19 — — WO claimed
EP-4228691-A2 LUNG TREATMENT COMPOSITIONS Biosuperior Technology, Inc. (US) 2023-08-23 — — EP claimed
EP-4117670-A1 METHOD FOR THE TREATMENT OF A RESPIRATORY DISEASE, DISORDER, OR CONDITION RESULTING FROM A VIRAL INFECTION Softhale NV (BE) 2023-01-18 — — EP claimed
US-20220395454-A1 STAINLESS STEEL CAN FOR PRESSURISED METERED DOSE INHALERS CHIESI FARMACEUTICI S.P.A. (IT) 2022-12-15 — — US claimed
EP-4069189-A1 STAINLES STEEL CAN FOR PRESSURISED METERED DOSE INHALERS Chiesi Farmaceutici S.p.A. (IT) 2022-10-12 — — EP claimed
WO-2022082082-A2 LUNG TREATMENT COMPOSITIONS LEHRMAN SHERWOOD RUSS (US) 2022-04-21 — — WO claimed
WO-2003049791-A1 MEDICAL DEVICE AND METHOD FOR INHALATION OF AEROSOLIZED DRUG WITH HELIOX NUPHARMX, LLC (US) 2003-06-19 — — WO claimed
US-6461591-B1 STORAGE STABILITY JAGO RESEARCH AG (CH) 2002-10-08 — — US claimed
WO-2002072448-A1 INHALER WITH MEANS FOR IMPROVING CHEMICAL STABILITY OF MEDICINAL AEROSOL SOLUTION CONTAINED THEREIN CHIESI FARMACEUTICI S.P.A. (IT) 2002-09-19 — — WO claimed
EP-1241113-A1 Inhaler with means for improving chemical stability of medicinal aerosol solution contained therein CHIESI FARMACEUTICI S.p.A. (IT) 2002-09-18 — — EP claimed
EP-1014943-B1 MEDICAL AEROSOL FORMULATIONS JAGO RES AG (CH) 2002-06-19 — — EP claimed
EP-0904266-A4 NITROSATED AND NITROSYLATED COMPOUNDS AND COMPOSITIONS AND THEIR USE FOR TREATING RESPIRATORY DISORDERS NITROMED INC (US) 2001-09-19 — — EP claimed
EP-1014943-A1 MEDICAL AEROSOL FORMULATIONS Jago Research AG (CH) 2000-07-05 — — EP claimed
EP-0904266-A1 NITROSATED AND NITROSYLATED COMPOUNDS AND COMPOSITIONS AND THEIR USE FOR TREATING RESPIRATORY DISORDERS Nitromed, Inc. (US) 1999-03-31 — — EP claimed
WO-1998034595-A1 MEDICAL AEROSOL FORMULATIONS JAGO RESEARCH AG (CH) 1998-08-13 — — WO claimed
WO-1997034871-A1 NITROSATED AND NITROSYLATED COMPOUNDS AND COMPOSITIONS AND THEIR USE FOR TREATING RESPIRATORY DISORDERS NITROMED, INC. (US) 1997-09-25 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12616654-B2 Stainless steel can for pressurised metered dose inhalers CHRM5, CHRM3, CHRM2 NR3C2 18/4885PGR 206/4885NR3C1 33/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.